The Golden Triangle and the gaps: Rethinking UK biotech

In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you’ll hear from Hakan Goker, managing director at M Ventures and Maina Bhaman, partner at Sofinnova Partners. We explore the UK biotech ecosystem : from the Golden Triangle’s evolving role to the challenges of scaling companies, unlocking pension capital and staying globally competitive.

Host

Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests

Hakan Goker, Managing Director, M Ventures

Maina Bhaman, Partner, Sofinnova Partners

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Poddgruvan

The Golden Triangle and the gaps: Rethinking UK biotech

Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil

Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water

AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more

From fragile skin to living medicine: Lessons from RDEB

Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more

Portugal, Spain and the new biotech frontier

Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence

Rethinking hair loss treatment

ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck

France’s biotech ecosystem: science, capital and scale